We’re pleased to announce late breaking data at #EASLCongress from our Phase 2 combination study in primary biliary cholangitis (#PBC). Learn more: https://lnkd.in/eVqQ-ypf
Intercept Pharmaceuticals’ Post
More Relevant Posts
-
#CRAB #POLIMIXIN #CLSI "A Susceptible* category for polymyxins cannot be established because there is no MIC for which likely clinical efficacy can be predicted. When used, polymyxins should be administered at maximally tolerated doses and in combination with a second agent.”24 Work with your antimicrobial stewardship program to determine the appropriate lab testing and reporting strategy for your facility. If you are going to use a polymyxin as part of your treatment regimen, polymyxin B is preferred over colistin given its more favorable pharmacokinetic profile." Dr. Tamma interview 2024. (CLSI Newdoc).
To view or add a comment, sign in
-
▪️Diabetes Nurse Practitioner ▪️Diabetology ▪️Population Health ▪️Technology Integration ▪️Consulting
Closely following these compounding drugs for a couple years now, not because I primarily support million dollar pharmaceutical companies, but for patient SAFETY reasons. The obesity and T2dm epidemic demands glp1, gip1, and newer dosing and triple peptides. I firmly believe and see this in my own clinical practice, just as we do globally. We are reversing the metabolic syndrome and giving people years extra to live, while preventing CV events 🙌🏻 But… we have to look closer, become curious, ask difficult questions, examine the entire process, and demand more funding and research. I’d like to see ALL hands on deck with a regulatory process to prevent patient harm: pharmacists, HCP’s, state/federal lawmakers, and research teams together. There has to be a better way to “do no harm”. Human life is too precious.
Co-Founder & Chief Medical Officer at Accomplish Health | Healthcare Futurist | Clinical Assistant Professor of Medicine - OUHSC
At What Cost? Lilly finds bacteria, other impurities in Mounjaro, Zepbound knockoffs h/t Rajesh Aggarwal MD PhD FRCS FACS https://t.co/45ybYIah2j
Lilly finds bacteria, other impurities in Mounjaro, Zepbound knockoffs
reuters.com
To view or add a comment, sign in
-
In 2019, the Food and Drug Administration (FDA) determined that only zinc oxide and titanium dioxide were deemed safe and effective ingredients in sunscreen. Several frequently encountered sunscreen ingredients were found to potentially interfere with the functioning of the endocrine system, and traces of these substances were detected in our bloodstream, breast milk, and urine samples even weeks after their application. In 2021 almost 80 different sunscreen and after-sun products were found to contain benzene which is known to cause cancer in humans. To learn more, check out more here! https://lnkd.in/gYKmtpTq
To view or add a comment, sign in
-
-
Treating conditions that cause blindness irreversible without care. Educate the patient on taking proper care to avoid early morbidity from preventable complications of diabetes & AMD. Engage tpatient in their health
1. Does the mOCT look better with Eylea HD or with Vabsymo ? 2. In the Real world how clinician make decisions without BCVA which dries better and more stable CST? 3. Clinicians base our decisions differently than clinical trials so which for the clinician that treats to dry 4. I am less concerned about DME But DR blocking ANG2 and VEGF makes more sense than blocking just VEGF. So if E8 came before Vabysmo we would be so excited about this dual pathway!
2 is better than 1! This is impressive. I saw this patient last month with naive bilateral nAMD. Patient was fully covered and I could have used an off label agent, biosimilars, approved VEGF-A inhibitors but I used Faricimab to take advantage of dual inhibition (2 pathways) based on the science and data from TENAYA/LUCERNE as well as TRUCKEE showing rapid improvements in IRF, SRF, PED and subretinal heme. The result? WOW - please check out the OCT images. The patient is dry after a single injection of Faricimab in both eyes and the subretinal heme in the right eye is resolved. As physicians, data and science should always win over anything else because if we make treatment decisions based on science/data then patients win!! Let’s continue to work together to bring the best treatment options for our patients so they can have the best outcomes! Let’s continue to push our field forward! #2isbetterthan1 #dualinhibition #faricimab #TRUCKEE
To view or add a comment, sign in
-
-
Haematology Registrar at Peter Mac & RMH interested in lymphoid malignancies, immunotherapies, clinical trials and health policy
Our correspondence in the The Lancet Haematology led by Amar Kelkar regarding the AMLSG 09-09 trial adding gemtuzumab ozogamicin in NPM1-mutant AML "All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results" Endpoints and their interpretation matter! "Cumulative incidence of relapse" is not as straightforward as it sounds. Read more below or here: https://lnkd.in/eqP7eRag #leusm Shai Rich Bishal Chun
To view or add a comment, sign in
-
2 is better than 1! This is impressive. I saw this patient last month with naive bilateral nAMD. Patient was fully covered and I could have used an off label agent, biosimilars, approved VEGF-A inhibitors but I used Faricimab to take advantage of dual inhibition (2 pathways) based on the science and data from TENAYA/LUCERNE as well as TRUCKEE showing rapid improvements in IRF, SRF, PED and subretinal heme. The result? WOW - please check out the OCT images. The patient is dry after a single injection of Faricimab in both eyes and the subretinal heme in the right eye is resolved. As physicians, data and science should always win over anything else because if we make treatment decisions based on science/data then patients win!! Let’s continue to work together to bring the best treatment options for our patients so they can have the best outcomes! Let’s continue to push our field forward! #2isbetterthan1 #dualinhibition #faricimab #TRUCKEE
To view or add a comment, sign in
-
-
🎉 Check out the top articles of the week from onthepen.com! Learn about the new generic liraglutide, exciting gut bacteria study, and the latest on compound tirzepatide. Click the link to read more: https://wix.to/2illbIY #zepbound #mounjaro #onthepen
HOME | On The Pen
onthepen.com
To view or add a comment, sign in
-
Did you know that for ten percent of MSSP ACOs 2-to-4 percent of the total spending was for Part B drugs to treat age-related macular degeneration (AMD) in 2021? In the past five years, ACO expenditures for this progressive eye disease have surged by 29 percent due to increased utilization of Eylea ($1,641 per treatment) and decreased use of Avastin, a comparable, lower-cost alternative ($62 per treatment). Given the high variation in drug utilization by state, market, and organization, ACOs have opportunities to manage spending while maintaining quality of care. Read more about the variation in Part B drug spending for AMD and implications for ACOs in a new Institute for Accountable Care (IAC):
To view or add a comment, sign in
-
Carbohydrates chemistry | Glycoconjugate Cancer vaccine | Adjuvants | Glycopeptide chemistry | Photoredox catalysis | Natural products Synthesis |
Discover more about the new class of conjugate adjuvant here, "Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants.”
Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants
pubs.acs.org
To view or add a comment, sign in
-
NEW DRUGS anti-CRE The picture below shows the importance of the identification of the resistance mechanism for antimicrobial stewardship purposes. Clinicians get confused when exactly Aztreonam have to be added to Ceftazidime Avibactam. As we don't have Aztronam Avibactam, for NDM CRE treatment, we give Ceftazidime Avibactam and Aztreonam combination. #CRE #CarbapenemaseResistantEnterobacteriaceae #NewDrugAntiCRE #KPC #OXA48 #VIM #NDM
To view or add a comment, sign in
-